The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization
Open accessAbstract
Use of high-throughput, in vitro bioactivity data in setting a point-of-departure (POD) has the potential to accelerate the pace of human health safety evaluation by informing screening-level assessments. The primary objective of this work was to compare PODs based on high-throughput predictions of bioactivity, exposure predictions, and traditional hazard information for 448 chemicals. PODs derived from new approach methodologies (NAMs) were obtained for this comparison using the 50th (PODNAM, 50) and the 95th (PODNAM, 95) percentile credible interval estimates for the steady-state plasma concentration used in in vitro to in vivo extrapolation of administered equivalent doses. Of the 448 substances, 89% had a PODNAM, 95 that was less than the traditional POD (PODtraditional) value. For the 48 substances for which PODtraditional < PODNAM, 95, the PODNAM and PODtraditional were typically within a factor of 10 of each other, and there was an enrichment of chemical structural features associated with organophosphate and carbamate insecticides. When PODtraditional < PODNAM, 95, it did not appear to result from an enrichment of PODtraditional based on a particular study type (eg, developmental, reproductive, and chronic studies). Bioactivity:exposure ratios, useful for identification of substances with potential priority, demonstrated that high-throughput exposure predictions were greater than the PODNAM, 95 for 11 substances. When compared with threshold of toxicological concern (TTC) values, the PODNAM, 95 was greater than the corresponding TTC value 90% of the time. This work demonstrates the feasibility, and continuing challenges, of using in vitro bioactivity as a protective estimate of POD in screening-level assessments via a case study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model
Browne, P., Judson, R. S., Casey, W. M., Kleinstreuer, N. C., & Thomas, R. S. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b02641 · Cited by 276
Self-citationThe US Federal Tox21 Program: A strategic and operational plan for continued leadership
Thomas, R. (2018) · ALTEX · doi:10.14573/altex.1803011 · Cited by 229
Self-citation
Cited by
Image-based profiling for drug discovery: due for a machine-learning upgrade?
Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D., & Carpenter, A. E. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00117-w · Cited by 389
New approach methodologies in human regulatory toxicology – Not if, but how and when!
Schmeisser, S., Miccoli, A., von Bergen, M., Berggren, E., Braeuning, A., Busch, W., Desaintes, C., Gourmelon, A., Grafström, R., Harrill, J., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.108082 · Cited by 380
Self-citationSmalling, K. L., Romanok, K. M., Bradley, P. M., Morriss, M. C., Gray, J. L., Kanagy, L. K., Gordon, S. E., Williams, B. M., Breitmeyer, S. E., Jones, D. K., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.108033 · Cited by 262
Nyffeler, J., Willis, C., Lougee, R., Richard, A., Paul-Friedman, K., & Harrill, J. A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114876 · Cited by 136
Self-citationNyffeler, J., Willis, C., Harris, F. R., Foster, M. J., Chambers, B., Culbreth, M., Brockway, R. E., Davidson-Fritz, S., Dawson, D., Shah, I., et al. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116513 · Cited by 67
Self-citation
Metadata
- Authors
- Paul Friedman, K., Gagne, M., Loo, L.-H., Karamertzanis, P., Netzeva, T., Sobanski, T., Franzosa, J. A., Richard, A. M., Lougee, R. R., Gissi, A., Lee, J.-Y. J., Angrish, M., Dorne, J. L., Foster, S., Raffaele, K., Bahadori, T., Gwinn, M. R., Lambert, J., Whelan, M., Rasenberg, M., Barton-Maclaren, T., & Thomas, R. S.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-18
- Volume
- 173
- Issue
- 1
- Pages
- 202-225
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2973521279
- Cited by
- 248
- References
- 3
- FWCI
- 28.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. https://app.cochat.ai/papers/10.1093/toxsci/kfz201
- The paper
- Paul Friedman, K., Gagne, M., Loo, L.-H., Karamertzanis, P., Netzeva, T., Sobanski, T., Franzosa, J. A., Richard, A. M., Lougee, R. R., Gissi, A., Lee, J.-Y. J., Angrish, M., Dorne, J. L., Foster, S., Raffaele, K., Bahadori, T., Gwinn, M. R., Lambert, J., Whelan, M., . . . Thomas, R. S. (2020). Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfz201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.